Raymond James & Associates Surface Oncology, Inc. Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$2.65 - $5.08 $48,741 - $93,436	-18,393 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$4.73 - $7.9 $267,268 - $446,389	-56,505 Reduced 75.44%	18,393 $88,000
Q3 2021 Nov 02, 2021	SELL	$5.16 - $7.98 $161,533 - $249,813	-31,305 Reduced 29.48%	74,898 $567,000
Q2 2021 Aug 11, 2021	BUY	$6.45 - $9.09 $49,613 - $69,920	7,692 Added 7.81%	106,203 $792,000
Q1 2021 May 14, 2021	BUY	$7.25 - $13.82 $409,436 - $780,470	56,474 Added 134.34%	98,511 $768,000
Q4 2020 Feb 12, 2021	SELL	$6.87 - $10.48 $316,033 - $482,100	-46,002 Reduced 52.25%	42,037 $388,000
Q3 2020 Nov 04, 2020	BUY	$5.06 - $7.23 $445,477 - $636,521	88,039 New	88,039 $607,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.